CNS Focus Pasithea is a clinical-stage biotechnology company targeting central nervous system disorders with a pipeline around next-generation MEK inhibitors, signaling potential partnerships in neuro-oncology, neurofibromatosis related therapies, and translational neuroscience collaborations.

Clinical Milestones Active Phase I dose-escalation study of PAS-004 with abstract presentations at major oncology congresses (ESMO 2026) indicate near-term pre-commercial engagement opportunities with clinical trial networks, investigator sites, and contract research organizations seeking CNS/MAPK pathway data.

Leadership Update New Chief Medical Officer appointed in 2026 suggests strategic clinical development expansion and stronger clinical operations, creating openings for advisory, KOL engagement, and sponsored research aligned with PAS-004 milestones.

Capital & Growth Recent $60M public funding and a total funding of $104M point to ongoing liquidity for expansion, enabling partnerships in manufacturing, CRO/CMC activities, and long-term collaborations with specialty pharma or biotech co-development partners.

Market Positioning Smaller headcount with focused niche in CNS and NF1-related indications combined with active investor relations and industry conference presence provides a door for strategic alliances, licensing discussions, and early-access programs with larger pharma players seeking niche CNS assets.